Testing effectiveness (Phase 2)Study completedNCT01961921
What this trial is testing
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 27